Key result
A combination of miRNA-130b-3p, miR-150-5p, and HDL cholesterol discriminated between large and small visceral adipocytes (AUC 0.872; 95% CI 0.747-0.996).
Why the study?
In obesity, the interrelation between adipocyte hypertrophy and visceral adipose tissue fibrosis remains unclear, and noninvasive biomarkers to assess visceral adipose tissue quality are needed.
Can circulating miRNAs accurately estimate visceral adipose tissue adipocyte size and fibrosis in patients with obesity?
Observational
Can circulating miRNAs accurately estimate visceral adipose tissue adipocyte size and fibrosis in patients with obesity?
Effect estimate: AUC 0.872 (95% CI 0.747-0.996)
Circulating miRNAs combined with HDL cholesterol can accurately estimate visceral adipose tissue adipocyte size and fibrosis, offering a non-invasive liquid biopsy approach to subphenotype obesity.
May support non-invasive visceral adipocyte sizing in obesity; leaves open validation and clinical utility.
OBJECTIVE: In obesity, adipocyte hypertrophy is detrimental to health, but its' interrelation with fibrosis in the visceral adipose tissue (VAT) depot remains unclear. Because VAT is less accessible via biopsy, biomarkers for VAT quality are needed. The authors hypothesized that VAT adipocyte size and fibrosis are interrelated and can be estimated by circulating microRNAs (circ-miRNAs), contributing to subphenotyping obesity. METHODS: ). Circ-miRNAs were sequenced (Next Generation Sequencing). RESULTS: Participants with above- versus below-median VAT adipocyte area exhibited metabolic dysfunction but lower total and pericellular fibrosis. VAT adipocyte size remained associated with metabolic dysfunction even when controlling for BMI or VAT fibrosis in the entire cohort, as in matched-pairs subanalyses. Next Generation Sequencing uncovered 22 and 6 circ-miRNAs associated with VAT adipocyte size and fibrosis, respectively, with miRNA-130b-3p common to both analyses. The combination of miRNA-130b-3p + miR-150-5p + high-density lipoprotein cholesterol discriminated among those with large versus small VAT adipocytes (receiver operating characteristic-area under the curve: 0.872 [95% CI: 0.747-0.996]), whereas miRNA-130b-3p + miRNA-15a-5p + high-density lipoprotein cholesterol discriminated among those with low and high fibrosis (receiver operating characteristic-area under the curve: 0.823 [95% CI: 0.676-0.97]). CONCLUSIONS: These findings suggest that VAT adipocyte size and fibrosis are inversely correlated in obesity and can be estimated by distinct circ-miRNAs, providing a potential tool to subphenotype obesity via a liquid biopsy-like approach to assess VAT health in nonsurgical patients.
No takes yet. Share an insight, caveat, or question.
Pincu et al. (2023) conducted an observational in Obesity. Above-median VAT adipocyte area vs. Below-median VAT adipocyte area was evaluated on Discrimination of large versus small VAT adipocytes using miRNA-130b-3p + miR-150-5p + HDL cholesterol (AUC 0.872, 95% CI 0.747-0.996). A combination of miRNA-130b-3p, miR-150-5p, and HDL cholesterol discriminated between large and small visceral adipocytes (AUC 0.872; 95% CI 0.747-0.996).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: